Cooperative Agreement U01CA295053
Award Date 9/19/25
Completion Date 8/31/29
Dollars Obligated $4.2M
Federal Agency
Federal Grant Program
Assistance Type
Cooperative Agreement
Place of Performance
Washington, USA
Similar Awards
- The National Cancer Institute (NCI) awarded a $432,098 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Fred Hutchinson Cancer Center in Seattle, Washington. The grant, awarded on August 4, 2025, supports research to understand the role of HIV persistence and treatment response in Kaposi Sarcoma (KS), a cancer caused by the Kaposi Sarcoma Herpesvirus that disproportionately impacts people with HIV, especially in Sub-Saharan Africa. The research aims to identify...
- This Cooperative Agreement was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), under the Cancer Biology Research program (CFDA 93.396). The $4,857,475 award supports a 4-year project to develop a strategically engineered multi-antigen vaccine against Kaposi sarcoma-associated herpesvirus (KSHV) infection. The project aims to generate potent antibody and T-cell immune responses to protect against KSHV infection and reduce the risk of associated...
- The U.S. Department of Defense's Defense Health Agency awarded a $5,149,107 Project Grant to the Fred Hutchinson Cancer Center, doing business as the Seattle Cancer Care Alliance, to conduct research under the Military Medical Research and Development (CFDA 12.420) program. The research aims to define human correlates of super-evasive disseminated tumor cells, understand their pathological relevance, and explore methods to eradicate them. The project will be conducted over a 4-year period from...
- This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396) provides $411,400 to Northwestern University to develop and characterize a cell culture model of Kaposi's sarcoma (KS). The primary objective is to identify KSHV-induced cellular genes that promote the loss of contact inhibition of proliferation (CIP) in KSHV-infected lymphatic endothelial cells (KLECs), which are believed to be the cell of origin for KS tumors. The...
- This $1,349,322 Project Grant awarded by the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research on how the Kaposi's sarcoma-associated herpesvirus (KSHV) manipulates cellular metabolic pathways and the epitranscriptome to maximize latent and lytic infection. The primary awardee, the University of Pittsburgh, will identify KSHV-regulated methylation marks on the mRNA-modifying enzyme METTL16 and determine their impact on the S-adenosylmethionine (SAM) cycle. The...
- This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $877,104.00 to Brigham & Women's Hospital Inc. to conduct research on Kaposi's Sarcoma-Associated Herpesvirus (KSHV) infection and persistence. The research aims to investigate the molecular mechanisms underlying the impact of KSHV on immune cells such as monocytes, macrophages, and B cells. This includes computational analyses of...
- This $220,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research by the Fred Hutchinson Cancer Center to conduct a novel clonal lineage tracing study of HIV-specific natural killer (NK) memory cells. The project aims to identify and characterize HIV-specific NK memory cell clones by leveraging a technique called ASAP-seq, which uses mitochondrial DNA mutations as barcodes to track NK...
- This $175,978 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) is funding research by the Fred Hutchinson Cancer Center, doing business as the Seattle Cancer Care Alliance, to study the role of ARID1A mutations in intrahepatic cholangiocarcinoma. The award period is from August 1, 2024 to July 31, 2026. The funding will support the organization's biomedical research and provision of medical care services related to...
- The federal Project Grant award of $1,578,836.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) in developing and exploiting a third-generation prostate cancer dependency map to identify cancer vulnerabilities and treatment targets. The award, which runs from August 1, 2024 to July 31, 2027, will enable the research organization to conduct innovative...
- This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research), supports research to investigate the activating and inhibitory signals that regulate the function of CD8 T cells in human tissues. The $857,346 grant, awarded on January 17, 2025, will fund a project led by the Fred Hutchinson Cancer Center in Seattle, Washington, to define the balance of pro- and anti-inflammatory signals, in the...